Public release date: 26-Jun-2012 [ | E-mail | Share ] Contact: David Eve celltransplantation@gmail.com Cell Transplantation Center of Excellence for Aging and Brain Repair Putnam Valley, NY. (June 26 , 2012) Researchers in Japan who evaluated the risks and efficacy of transplanting two varieties of stem cells into mouse cochlea have concluded that both adult-derived induced pluripotent stem (iPS) cells and mouse embryonic stem (ES) cells demonstrate similar survival and neural differentiation capabilities. However, there is a risk of tumor growth associated with transplanting iPS cells into mouse cochleae. Given the potential for tumorigenesis, they concluded that the source of iPS cells is a critical issue for iPS cell-based therapy. Their study is published in a recent issue of Cell Transplantation (21:4), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, "Hearing loss affects millions of people worldwide," said Dr. Takayuki Nakagawa of the Department of Otolaryngology, Graduate School of Medicine, Kyoto University, Japan. "Recent studies have indicated the potential of stem-cell based approaches for the regeneration of hair cells and associated auditory primary neurons. These structures are essential for hearing and defects result in profound hearing loss and deafness." The authors noted that embryonic stem cells have previously been identified as promising … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/xlqrsk/skeletal_biology_a) has announced the addition of John Wiley and Sons Ltd's new book "Skeletal Biology and Medicine II: Bone and cartilage homeostasis and bone disease" to their offering. The volume features current basic, clinical, and translational research on aspects of skeletal morphogenesis and remodeling in health and disease. Papers survey vital new insights into the mechanisms of bone development and restructuring, including cellular and mechanical triggers, receptors and signaling pathways. Also covered are the effects of other physiological systems and disease states, such as immune system inflammation, diabetes, infection, and cancer on musculoskeletal health. Recent findings are shaping therapeutic directions that focus on both anti-resorptive and anabolic therapies. Basic scientists, clinical investigators, and clinicians with interests spanning endocrinology, physiology, cell biology, pathology, genetics, molecular biology, rheumatology, oncology, and other areas that relate to bone development and homeostasis will find this a valuable resource for the most recent developments in skeletal biology and medicine. This volume presents manuscripts stemming from the 4th New York Skeletal Biology and Medicine Conference, held at Mount Sinai School of Medicine in New York City on April 27-30, 2011. The papers included in this volume include two of the topic areas … Continue reading →

The Sugar Land company involved in Gov. Rick Perry's unlicensed adult stem-cell procedure is rife with basic manufacturing problems, according to the U.S. Food and Drug Administration. In a report one expert called a blow to the entire adult stem-cell industry, the FDA found that Celltex Therapeutics Corp. cannot guarantee the sterility, uniformity and integrity of stem cells it takes from people and then stores and grows for eventual therapeutic reinjection. "You have not performed a validation of your banking and thawing process to assure viability" of the stem cells, reads the April 27 report, meaning that the company cannot verify the cells are alive. The FDA report, which followed an April 16-27 inspection of Celltex, was released under the Freedom of Information Act Monday to the Houston Chronicle and a University of Minnesota bioethicist who complained in February that Celltex is a potential danger to patients and not in compliance with federal law. The report, partially redacted, was not accompanied by a warning letter. A former FDA official who asked not to be identified, however, said the deficiencies - 79 in all, from incorrectly labeled products to failed sterility tests - are so serious that Celltex risks being shut … Continue reading →